Orbimed Advisors Trims $125 After Breakout Year in Biotech
A major biotech stake shift signals evolving risk appetite. We break down the $125 million trim by ORBIMED Advisors, ...
After overspending, assess the cause, cut excess, adjust allocations, and implement a tighter tracking routine to prevent recurrence.
23,645 articlesA major biotech stake shift signals evolving risk appetite. We break down the $125 million trim by ORBIMED Advisors, ...
As inflation cools, a 65-year-old with $7,000 a month must navigate taxes, geography, and housing to determine if ret...
A director sold 33,000 Clear Secure shares worth about $1.5 million, sparking questions about the stock's outlook. Th...
As Medicare Part B costs climb in 2026, delaying enrollment can trigger lifelong penalties. Experts warn retirees to ...
A major sports policy change bars transgender women from competing in women's events. This decision carries far more ...
This week brought a sharp turn for Zscaler investors. Despite beating earnings estimates, the stock moved lower as gu...
A major stake sale can ripple through markets and portfolios. This article breaks down what arena capital sells milli...
Netflix is trading well below its latest peak. This article breaks down what the drop means, what history suggests ab...
SpaceX dazzled investors at IPO, but the price soon drifted below debut. This article shows how a $10,000 investment ...
When a stock pops today, investors want the real story behind the move. This guide breaks down what drove SLB stock t...
Cathie Wood goes selling has people watching Ark Invest closely. This article breaks down three key trims, the reason...
The CAAP 2026 earnings call offers more than quarterly results. This guide breaks down revenue drivers, margins, and ...